The U.S. Food and Drug Administration (FDA) has approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults. The approval makes Qulipta the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic AND chronic migraine. People living with chronic migraine experience headaches for 15 or more days per month, with at least eight of those days associated with migraine.
CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology, and studies have shown that CGRP levels are elevated during migraine attacks. Qulipta blocks CGRP through a once-daily dose and is available in three strengths for the preventive treatment of episodic migraine – 10 mg, 30 mg and 60 mg. Only the 60 mg dose of Qulipta is approved for the preventive treatment of chronic migraine.
The most common side effects of Qulipta are nausea, constipation, and fatigue/sleepiness. These are not all the possible side effects of Qulipta. If you have migraines, please make an appointment to discuss this and other possible treatments with a MCHN provider.
–Alice Wong, NP